PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩3,500 per share · Prices as of the 2026-10-02 close
Samyang Holdings, which posted a large net loss in Q4 2025, has shown consecutive improvement in operating profit and net profit in Q1-Q2 2026.
Q2 2026 revenue reached 963.0 billion won with operating profit of 60.5 billion won, the highest operating margin in the past five quarters
The Q4 2025 net loss attributable to owners of 266.7 billion won dragged full-year 2025 owners' net loss to 199.95 billion won, reducing equity
The chemical segment grew in engineering plastics and premium ion-exchange resin but faces intensifying domestic competition from capacity expansions
Subsidiary Samyang Packaging improved its Q2 2026 operating margin to about 12.9% on aseptic and recycling business expansion
The debt ratio rose from 76.5% in 2024 to 98.8% in 2025 as subsidiary capex needs and the net loss compounded
Samyang Holdings, established in 1924, is the holding company of Samyang Group, overseeing holding operations and investment/leasing businesses.
Within the group structure, Samyang Holdings is the largest shareholder of core subsidiary Samyang Corporation with a 61.83% stake, and Samyang Corporation in turn owns 59.40% of Samyang Packaging and 50.02% of Samyang KCI, forming a multi-tiered governance structure.
Consolidated subsidiaries total 14, comprising three listed entities (Samyang Corporation, Samyang Packaging, Samyang KCI) and 11 unlisted companies. The business spans four pillars: food, chemicals, packaging, and pharma-bio.
The food segment is shifting its portfolio from base materials such as sugar, starch syrup, and flour toward specialty products including the alternative sweetener allulose and the dietary fiber isomalto-oligosaccharide.
The chemical segment centers on engineering plastics such as polycarbonate, ion-exchange resins, and BPA-related materials, with engineering plastics demand closely tied to TV, mobile phone, and automotive markets.
Subsidiary Samyang Packaging, which commercialized Korea's first PET bottle, holds the leading share in the domestic aseptic packaging market and has recently expanded into recycled PET (rPET) operations.
In pharma-bio, Samyang Biopharm holds the world's No.1 position in biodegradable surgical suture yarn, with over 90% of suture revenue derived from overseas exports and Europe accounting for 30% of export volume.
The group is cultivating semiconductor, battery, and personal-care materials along with eco-friendly white-bio materials such as isosorbide as new growth pillars.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩907.5B | ₩43.1B | 4.7% |
| 2025Q3 | ₩889.6B | ₩46.4B | 5.2% |
| 2025Q4 | ₩685.2B | -₩12.3B | −1.8% |
| 2026Q1 | ₩838.3B | ₩29.2B | 3.5% |
| 2026Q2 | ₩963B | ₩60.5B | 6.3% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩3.3T | ₩132.3B | ₩71B | 4.0% | 4.0% | 80.2% |
| 2023 | ₩3.2T | ₩94.8B | ₩172.4B | 3.0% | 8.6% | 83.7% |
| 2024 | ₩3.6T | ₩127.5B | ₩28.3B | 3.6% | 1.3% | 76.5% |
| 2025 | ₩3.3T | ₩108.8B | -₩200B | 3.2% | −11.0% | 98.8% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-17
Looking at annual results, revenue moved from 3.317 trillion won in 2022 to 3.211 trillion won in 2023, rose to 3.553 trillion won in 2024, then slipped slightly to 3.348 trillion won in 2025.
Operating profit fell from 132.3 billion won in 2022 to 94.8 billion won in 2023, recovered to 127.5 billion won in 2024, then declined again to 108.8 billion won in 2025.
The bigger issue is net profit: after posting owners' net profit of 28.3 billion won in 2024, the company swung to an owners' net loss of 199.95 billion won in 2025, a swing far larger than the decline in operating profit alone would suggest.
Tracing this quarter by quarter, results through Q3 2025 were solid, with revenue of 889.6 billion won, operating profit of 46.4 billion won, and owners' net profit of 17.2 billion won, but Q4 2025 revenue dropped sharply to 685.2 billion won with an operating loss of 12.3 billion won, while the owners' net loss widened to 266.7 billion won.
The fact that the net loss (266.7 billion won) was more than 20 times the operating loss (12.3 billion won) suggests a substantial non-operating loss item was recognized in that quarter.
Since then, results have improved for two consecutive quarters: Q1 2026 posted revenue of 838.3 billion won, operating profit of 29.2 billion won, and owners' net profit of 21.0 billion won, while Q2 2026 recorded revenue of 963.0 billion won, operating profit of 60.5 billion won, and owners' net profit of 32.5 billion won.
In operating margin terms, this was 4.7% in Q2 2025, 5.2% in Q3 2025, a loss in Q4 2025, 3.5% in Q1 2026, and 6.3% in Q2 2026, the highest profitability of these recent quarters.
Consolidated owners' equity stood at 1.825 trillion won in 2025, down from 2.107 trillion won in 2024, while the debt ratio jumped from 76.5% to 98.8%, reflecting the combined effect of equity erosion from the net loss and rising liabilities.
In the chemical segment, profitability has partly improved thanks to growth in premium engineering plastics and ion-exchange resins, but the segment shows a dual structure: engineering plastics demand is closely tied to TV, mobile phone, and automotive end markets, while BPA benefits from improving epoxy resin demand even as domestic competitor capacity expansions intensify competition.
Semiconductor materials are cited as an area of expected long-term growth driven by the spread of AI, big data, and IoT.
In packaging, the recycled PET (rPET) business is expected to expand in scale amid environmental regulation and policies mandating higher recycled-plastic usage ratios, and Samyang Packaging posted an operating margin of about 12.9% in Q2 2026 on new demand generation in the aseptic and container businesses and the formation of the recycling market.
The pharma-bio business, anchored by its global No.1 position in biodegradable surgical sutures, maintains a global supply network serving over 190 companies across 45 countries, giving it a relatively defensive character.
Overall, the holding company's results reflect a mix of subsidiary-level cycles, with chemicals passing through an oversupply phase while packaging and pharma-bio form structural growth pillars, creating clear divergence across the portfolio.
The group has pursued a mid-to-long-term strategy of upgrading its portfolio toward specialty and global businesses by developing high-value-added materials across food, chemicals, and pharma-bio, shifting food toward specialty materials like allulose and isomalto-oligosaccharide, and chemicals from polycarbonate-centered engineering plastics toward strengthened eco-friendly materials.
Samyang Innochem completed a plant in Gunsan, North Jeolla Province, producing isosorbide, a white-bio material derived from plant-based starches such as corn, aiming to substitute petroleum-derived materials like BPA.
Samyang Packaging is pursuing the introduction of recycled PET chip production equipment at its Sihwa plant, offering higher purity than recycled PET flake, with potential expanded uses in apparel-grade yarn and food/cosmetics containers.
NICE Investors Service stated that while Samyang Packaging's net debt has risen somewhat due to capex for upgrading its container business in 2025-2026, it expects gradual debt reduction and improved financial stability going forward given stable earnings capacity and low routine capex burden.
The pharma-bio segment continues to pursue new drug R&D and global manufacturing base expansion, while semiconductor, battery, and personal-care materials businesses are presented as the group's new growth pillars.
However, intensifying competition from domestic competitor capacity expansions in the chemical segment remains a variable that will influence the pace of any margin recovery.
Samyang Holdings has tended to trade at a discount to net asset value, which may be related to the structural discount typical of diversified business holding companies.
The large net loss in 2025 reduced owners' equity from the prior year, and the company has not yet fully exited net-loss territory on a trailing four-quarter basis, limiting the usefulness of conventional earnings-multiple comparisons.
That said, two consecutive quarters of improving operating and net profit in Q1 and Q2 2026 confirm a shift from loss to profit, and the market appears to be assessing whether this recovery will be sustained.
The company has maintained a policy of paying a consistent level of per-share cash dividends each year, though the dividend yield itself changes daily with the share price and cannot be pinned to a specific figure here.
Ultimately, valuation for this stock sits at the intersection of a net-asset-based discount and the question of whether the recent earnings recovery proves durable.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-17
Both Q1 and Q2 2026 saw operating profit and owners' net profit increase quarter-over-quarter, moving away from the Q4 2025 loss. Q2 2026's operating margin of about 6.3% was the highest of the past five quarters.
This appears to reflect a combination of expanded sales volume and cost efficiency at major subsidiaries in chemicals and packaging.
Samyang Biopharm holds the world's No.1 position in biodegradable surgical suture yarn, with over 90% of suture revenue from overseas exports and Europe accounting for 30% of export volume. This can function as a relatively stable revenue source less tied to domestic economic swings.
Samyang Packaging saw Q2 2026 revenue and operating profit rise 9.5% and 21.4% year-over-year, respectively, driven by new demand generation in containers and aseptic packaging and the full-scale formation of the recycled PET market. Fixed-cost dilution from higher sales volume also contributed to margin improvement.
While the Q4 2025 operating loss was only 12.3 billion won, the owners' net loss reached 266.7 billion won, suggesting a substantial non-operating loss factor was recognized. The possibility of such non-operating losses recurring adds uncertainty to future earnings forecasts.
The engineering plastics and BPA-related businesses face intensifying competition from domestic competitor capacity expansions, which is cited as a constraint on margin recovery despite improving demand. The business is also exposed to fluctuations in downstream TV, mobile phone, and automotive demand.
Owners' equity fell from 2.107 trillion won in 2024 to 1.825 trillion won in 2025 due to the net loss, and the debt ratio rose from 76.5% to 98.8%. Rising net debt from subsidiary capex expansion is occurring simultaneously, making the pace of any balance-sheet improvement worth monitoring.
If net-income swings far larger than operating income, as seen in Q4 2025, recur, quarterly earnings forecasting could become more difficult. Given the holding company structure, the simultaneous reflection of multiple subsidiaries' results and equity-method/valuation items can amplify volatility.
The chemical segment is exposed to oversupply in BPA and engineering plastics and intensifying competition from domestic competitor capacity expansions. A slowdown in downstream TV, mobile phone, or automotive demand could negatively affect related revenue and margins.
With the debt ratio rising to 98.8% in 2025, expanded capex at subsidiaries such as Samyang Packaging is contributing to higher net debt. NICE Investors Service projected gradual debt reduction, but if investment plans are delayed or expanded, the financial burden could exceed expectations.
Check the Q3 2026 preliminary earnings disclosure — a key point to verify whether the profit recovery seen in Q1-Q2 2026 continues and whether chemical segment margins improve.
Monitor the startup of Samyang Packaging's recycled PET chip production line at the Sihwa plant and its revenue contribution — a key point to watch is how much the recycling business actually contributes to results.
Track whether BPA and engineering plastics pricing pressure and the effects of domestic competitor capacity expansion persist — important for gauging how much competition constrains the pace of margin recovery.
Confirm full-year 2026 finalized results and dividend policy via the annual business report and shareholders' meeting — the key item to check is whether a full annual return to profit was achieved after the 2025 net loss.
Samyang Holdings is a diversified business holding company spanning food, chemicals, packaging, and pharma-bio that suffered a large net loss in Q4 2025 but has shown improving operating and net profit for two consecutive quarters in Q1-Q2 2026.
The chemical segment continues to face margin pressure from intensifying domestic competitor capacity expansion, while the packaging subsidiary is improving profitability through aseptic and recycling business expansion, and the pharma-bio segment maintains a stable export base built on its world-leading suture business.
The equity decline and debt ratio rise to 98.8% in 2025 remain a financial burden, and the possibility of a recurrence of the large non-operating loss factor seen in Q4 2025 adds uncertainty to earnings forecasts.
Ultimately, the key question for this stock is whether the recent two-quarter profit recovery represents a structural improvement or a temporary rebound, to be confirmed through upcoming quarterly results.
Investors should watch the next quarterly earnings disclosure alongside margin trends in the chemical and packaging segments and the pace of balance-sheet improvement.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.